VOGX news

Latest 3 stories · newest Nov 6, 2026

VOGX

Vogenx posts cash-rich Q3 and launches Phase 2b study

Vogenx raised $84.4M from a $93.4M IPO in August 2026 to strengthen its balance sheet with $82.1M in liquidity and initiated its EMERGE clinical trial for mizagliflozin in post-bariatric hypoglycemia.

Offering Nov 6, 2026 sentiment +0.65 SEC filing ↗

VOGX

Vogenx Appoints Gorman as Chief Commercial Officer

Vogenx named board member Richard Gorman as Chief Commercial Officer, tapping his 30-year biopharmaceutical experience to strengthen its commercial strategy and readiness following its IPO.

Leadership Oct 9, 2026 sentiment +0.40 SEC filing ↗

VOGX

Vogenx Appoints Ken Toombs to Board of Directors

Vogenx announced the appointment of former PA Consulting CEO Ken Toombs, an industry veteran with life sciences expertise, to its board. The addition of independent oversight is intended to support operations as the company scales.

Leadership Sep 22, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same VOGX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/VOGX/newsSTART FREE